Naratriptan hydrochloride

Cat. No.: HY-B0197A
CAS No.: 143388-64-1
Molecular Formula: C₁₇H₂₆ClN₃O₂S
Molecular Weight: 371.93
Target: 5-HT Receptor
Pathway: GPCR/G Protein; Neuronal Signaling
Storage: Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 35 mg/mL (94.10 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Solvent Mass</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.6887 mL</td>
<td>13.4434 mL</td>
<td>26.8868 mL</td>
<td></td>
</tr>
<tr>
<td>5 mM</td>
<td>0.5377 mL</td>
<td>2.6887 mL</td>
<td>5.3774 mL</td>
<td></td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2689 mL</td>
<td>1.3443 mL</td>
<td>2.6887 mL</td>
<td></td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Naratriptan hydrochloride is a selective 5-HT1 receptor subtype agonist and is a triptan drug that is used for the treatment of migraine headaches. Target: 5-HT1 Receptor
Naratriptan is a triptan drug marketed by GlaxoSmithKline and is used for the treatment of migraine headaches. Naratriptan is available in 2.5 mg tablets. It is a selective 5-HT1 receptor subtype agonist. Naratriptan is used for the treatment of the acute migraine attacks and the symptoms of migraine, including severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound or light. The causes of migraine are not clearly understood; however, the efficacy of naratriptans and other triptans is believed to be due to their activity as 5HT (serotonin) agonists. A meta-analysis of 53 clinical trials has shown that all triptans are effective for treating migraine at marketed doses and that naratriptan, although less effective than sumatriptan and rizatriptan was more effective than placebo in reducing migraine symptoms at two hours and efficacy was demonstrated in almost two thirds of subjects after four hours of treatment.

REFERENCES

Product Data Sheet

Inhibitors • Agonists • Screening Libraries

www.MedChemExpress.com

Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898                  Fax: 609-228-5909                  E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA